How well does prime editing actually correct disease-causing mutations?
In lab-grown human cells, prime editing can correct disease mutations with impressive efficiency. For cystic fibrosis, researchers boosted correction of the common F508del mutation from under 0.5% to 58% in bronchial epithelial cells by combining six optimization strategies, and to 25% in patient-derived airway cells [1]. This correction restored CFTR ion channel function to over 50% of normal levels, matching the effect of a leading drug combination [1]. For chronic granulomatous disease, prime editing corrected the delGT mutation in over 75% of patient blood stem cells, restoring NADPH oxidase activity to about 80% of healthy donor levels [2]. These results show that, at the cellular level, prime editing can be both highly efficient and functionally restorative.
Is prime editing safe and does the correction last?
Safety data from these studies is encouraging, though still limited to animal models and lab-grown cells. In chronic granulomatous disease research, genome-wide assays detected no off-target edits, unintended edits, or chromosomal rearrangements after prime editing in human blood stem cells [2]. When those edited cells were transplanted into mice, they maintained normal stem cell function and produced corrected blood cells for at least 16 weeks, with over 87% of long-term stem cells carrying the fix [2]. For phenylketonuria, a single dose of prime editing components delivered via lipid nanoparticles to humanized mice completely normalized blood phenylalanine levels within 48 hours, and the effect was durable [5]. These findings suggest that prime editing can be precise and the correction can persist, but long-term safety in humans has not yet been tested.
What are the main hurdles to using prime editing in patients?
The biggest challenge is delivering the editing machinery into enough of the right cells in a patient's body. In cystic fibrosis studies, correction efficiency in patient-derived lung cells was only 2.81% before adjusting for low transfection efficiency (just 11.9%), highlighting that delivery methods are a major bottleneck [3]. Even the best results—25% correction in patient airway cells [1]—may not be enough to cure a disease like cystic fibrosis, which likely requires correction in a large fraction of lung cells. Another hurdle is that some genome regions, like the AT-rich area around the CFTR F508del mutation, are inherently harder to edit [3]. Researchers are actively working on better delivery vectors, such as lipid nanoparticles [5] and viral vectors, but these have not yet been optimized for prime editing in humans.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 2 from 2024 or later, 4 in Q1 journals, collectively cited 148 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 82 papers retrieved from a database of over 500 million.
Sources used in this answer
Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells
By combining six optimizations, prime editing corrected the CFTR F508del mutation in up to 58% of bronchial epithelial cells and 25% of patient-derived airway cells, restoring ion channel function to over 50% of normal levels with minimal off-target edits.
Prime Editing Efficiently and Precisely Corrects Causative Mutation in Chronic Granulomatous Disease, Restoring Myeloid Function: Toward Development of a Prime Edited Autologous Hematopoietic Stem Cell Therapy
Prime editing corrected the delGT mutation in over 75% of chronic granulomatous disease patient blood stem cells, restoring NADPH oxidase activity to ~80% of normal, with no detectable off-target edits or chromosomal rearrangements, and edited cells maintained function for 16 weeks in mice.
THE SELECTION OF OPTIMAL pegRNAs TO ENHANCE THE EFFICIENCY OF PRIME EDITING IN AT-RICH GENOME REGIONS
In AT-rich genome regions like the CFTR F508del site, prime editing correction efficiency was only 2.81% in patient lung cells due to low transfection efficiency (11.9%), underscoring the need for better delivery methods.
Transient inhibition of p53 enhances prime editing and cytosine base-editing efficiencies in human pluripotent stem cells
Co-delivering a dominant-negative p53 fragment (p53DD) enhanced prime editing efficiency in human pluripotent stem cells without compromising genome-wide safety, enabling creation of disease models for Parkinson's and progeria.
Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing
In a humanized mouse model of phenylketonuria, a single dose of prime editing components via lipid nanoparticles completely and durably normalized blood phenylalanine levels within 48 hours, nominating a drug candidate for further development.